Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.00

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $58.00.

A number of analysts recently issued reports on the stock. Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Monday, June 2nd. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a research note on Tuesday, May 27th. They set a "buy" rating and a $65.00 price objective for the company. Finally, Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMCR. T. Rowe Price Investment Management Inc. lifted its stake in shares of Immunocore by 5.2% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock worth $209,228,000 after acquiring an additional 351,610 shares during the period. Primecap Management Co. CA grew its position in Immunocore by 40.8% in the second quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company's stock worth $118,349,000 after acquiring an additional 1,092,824 shares in the last quarter. Bellevue Group AG boosted its holdings in Immunocore by 99.9% in the 2nd quarter. Bellevue Group AG now owns 2,441,830 shares of the company's stock valued at $76,625,000 after purchasing an additional 1,220,036 shares during the period. Baker BROS. Advisors LP increased its position in shares of Immunocore by 53.3% during the 1st quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock worth $68,913,000 after purchasing an additional 807,338 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Immunocore by 1.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after purchasing an additional 29,832 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Price Performance

Shares of IMCR traded up $0.15 during mid-day trading on Monday, reaching $32.64. 240,231 shares of the company's stock were exchanged, compared to its average volume of 337,203. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. The company has a 50-day simple moving average of $33.39 and a two-hundred day simple moving average of $31.25. Immunocore has a 52-week low of $23.15 and a 52-week high of $39.33. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -81.90 and a beta of 0.77.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The business had revenue of $130.65 million during the quarter, compared to analysts' expectations of $122.96 million. During the same period last year, the company posted ($0.23) EPS. The company's revenue was up 30.0% on a year-over-year basis. On average, sell-side analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.